Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation.
about
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsEvidence based diagnosticsQuantitative proteomics for cardiac biomarker discovery using isoproterenol-treated nonhuman primates.Mechanisms of renal hyporesponsiveness to ANP in heart failure.Plasma ProBNP Is Not a Specific Marker for Transient Myocardial Ischemia.ANP-induced signaling cascade and its implications in renal pathophysiologyEvaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories.The architecture of diagnostic research.NT-proBNP is associated with SYNTAX score and aortic distensibility in patients with stable CAD.The role of procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting outcome after cardiac surgery.Accuracy of N-terminal-pro-atrial natriuretic peptide in patients admitted to emergency department.Effective prediction of response to cardiac resynchronization therapy using a novel program of gated myocardial perfusion single photon emission computed tomography.Evaluation of QTc Interval Prolongation in Breast Cancer Patients after Treatment with Epirubicin, Cyclophosphamide, and Docetaxel and the Influence of Interobserver Variation.
P2860
Q24793837-E5F54599-7A3B-4572-A68E-94DECBC5278FQ27007849-B8E9E801-B42F-4837-A33F-476FA6C1412BQ33934950-AE87FF7B-9611-413E-9425-28E98593778BQ34669434-8D67052A-79D0-4C31-91AA-C0634188669FQ35202136-1CF4E54C-2BDA-4B6E-9882-5FB64FB080FDQ35609802-9961A77C-076C-4A18-8CC6-BD6592F26D7FQ35622455-A187FD4B-6D41-42F6-A7C7-02CFAE7C0583Q39379692-32CE6A26-A489-4C1C-9617-F4D05AA87EC0Q41829431-75F600BD-FA80-4F00-A2EE-D0152C6E9B1CQ48129791-15BAF52E-3096-4361-A972-0FEF50863D27Q48438639-2496C26B-0DC2-4E4C-A33F-DB630DB2FCA0Q48786011-CC6F2C50-AC5E-4D3D-B85D-06D2D89A38D3Q48930065-891A1BA3-73EF-409C-98FA-4DCAF8A13E2CQ50355427-26891022-76F0-4F1B-A11C-7804BA6DBF50
P2860
Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Cardiac natriuretic peptides f ...... n cardiac hormonal activation.
@en
Cardiac natriuretic peptides f ...... n cardiac hormonal activation.
@nl
type
label
Cardiac natriuretic peptides f ...... n cardiac hormonal activation.
@en
Cardiac natriuretic peptides f ...... n cardiac hormonal activation.
@nl
prefLabel
Cardiac natriuretic peptides f ...... n cardiac hormonal activation.
@en
Cardiac natriuretic peptides f ...... n cardiac hormonal activation.
@nl
P2093
P2860
P1476
Cardiac natriuretic peptides f ...... n cardiac hormonal activation.
@en
P2093
Donckier JE
Ketelslegers JM
Rousseau MF
Selvais PL
van Linden F
P2860
P304
P356
10.1046/J.1365-2362.1998.00338.X
P577
1998-08-01T00:00:00Z